自康方生物的AK112在关键Ⅲ期HARMONi-2研究中头对头击败“全球药王”K药后,双特异性肿瘤免疫疗法站上产业风口。市场目光随之聚焦:谁将成为下一个成功挑战者?7月24日,维立志博在香港联合交易所主板正式挂牌上市,股票代码为9887.HK,预计募集资金总额可达1.89亿美元(含绿鞋),其中所得款项净额约46.0%将用于核心产品LBL-024(4-1BB/PD-L1双抗)的持续临床开发。LBL...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.